Connect Biopharmaceuticals – based in Taicang, Suzhou, China and San Diego – reported positive topline data from the company’s Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis (AD).
If you are not happy with the results below please do another search
50 search results for:
Pfizer said the company’s Covid-19 vaccine, developed with BioNTech, demonstrated 100 percent effectiveness in the 12-15 year age group after four months. In other news, the U.S. Food and Drug Administration said that it could take over 55 years for the regulatory agency to review and release a complete report on the vaccine-related documentation the FDA currently holds in response to a lawsuit filed by scientists demanding to see the complete records.
Neurocrine Biosciences has partnered with Sosei Group Corporation to develop treatments that would address dementia, schizophrenia, and other types of neuropsychiatric disorders.
Fifteen medical and human rights groups are urging U.S. President Joe Biden to get personally engaged in a long-running fight to enact an intellectual property waiver for Covid-19 vaccines at the World Trade Organization, calling his leadership “a moral necessity.”
Switzerland-based Vifor Pharma is acquiring Spain’s Sanifit Therapeutics and Switzerland’s Inositec.
The Centers for Disease Control and Prevention (CDC) approved the use of Pfizer-BioNTech’s and Moderna’s vaccines as booster shots for all adults ages 18 years and up.
The White House confirmed Monday that more than 90 percent of 3.5 million federal employees covered by a presidential Covid-19 vaccine mandate have received at least one vaccine dose ahead of a November 22 deadline.
Pfizer Inc. said on November 22 the company’s Covid-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.
Obseva SA announced that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women was accepted for review by the United States Food and Drug Administration.
The U.S. Food and Drug Administration approved BioMarin Pharmaceutical’s Voxzogo (vosoritide) to improve growth in children 5 years of age and older with achondroplasia, a rare genetic disorder that causes the most common form of dwarfism.